592 related articles for article (PubMed ID: 28589310)
1. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey.
McCrary JM; Goldstein D; Boyle F; Cox K; Grimison P; Kiernan MC; Krishnan AV; Lewis CR; Webber K; Baron-Hay S; Horvath L; Park SB;
Support Care Cancer; 2017 Nov; 25(11):3485-3493. PubMed ID: 28589310
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
3. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy.
McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB
J Pain Symptom Manage; 2019 Dec; 58(6):1023-1032. PubMed ID: 31374367
[TBL] [Abstract][Full Text] [Related]
5. Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge.
Kandula T; Park SB; Cohn RJ; Krishnan AV; Farrar MA
Cancer Treat Rev; 2016 Nov; 50():118-128. PubMed ID: 27664395
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Mukai H; Katsumata N; Sunada Y; Watanabe T; Hausheer FH
Support Care Cancer; 2009 Dec; 17(12):1483-91. PubMed ID: 19330359
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review.
Haryani H; Fetzer SJ; Wu CL; Hsu YY
Oncol Nurs Forum; 2017 May; 44(3):E111-E123. PubMed ID: 28635977
[TBL] [Abstract][Full Text] [Related]
10. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
[TBL] [Abstract][Full Text] [Related]
11. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
[TBL] [Abstract][Full Text] [Related]
12. Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy.
Mizrahi D; Goldstein D; Kiernan MC; Robinson L; Pitiyarachchi O; McCullough S; Mendoza-Jones P; Grimison P; Boyle F; Park SB
Support Care Cancer; 2022 Jul; 30(7):5965-5974. PubMed ID: 35394563
[TBL] [Abstract][Full Text] [Related]
13. Nursing knowledge, practice patterns, and learning preferences regarding chemotherapy-induced peripheral neuropathy.
Smith EM; Campbell G; Tofthagen C; Kottschade L; Collins ML; Warton C; Ghosh B; Ronis DL; Mallory GA; Visovsky C
Oncol Nurs Forum; 2014 Nov; 41(6):669-79. PubMed ID: 25355022
[TBL] [Abstract][Full Text] [Related]
14. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
16. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
Kuroi K; Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Watanabe T; Bain S; Hausheer FH
Jpn J Clin Oncol; 2008 Nov; 38(11):748-54. PubMed ID: 18845520
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
18. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
Knoerl R; Weller E; Halpenny B; Berry D
BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
[TBL] [Abstract][Full Text] [Related]
19. Development of the consensus-based recommendations for Podiatry care of Neuropathy In Cancer Survivors (PodNICS): a Delphi consensus study of Australian podiatrists.
Dars S; Buckley E; Beckmann K; Roder D; Banwell H
J Foot Ankle Res; 2023 Jun; 16(1):33. PubMed ID: 37291602
[TBL] [Abstract][Full Text] [Related]
20. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
